# Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction

> **NCT00091117** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 80 (actual)

## Conditions studied

- Hepatic Complications
- Malignant Neoplasm

## Interventions

- **DRUG:** bortezomib
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00091117
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2013-03
- **Final completion:** —
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2013-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00091117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00091117, "Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00091117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*